TrialJournal of clinical pharmacology2025

Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic-Associated Fatty Liver Disease.

Islam R Younis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.